A recent article from The Wall Street Journal describes several funds
with large cash positions.
The current depressed valuation comes as a result of a generic filing and approval of Osmotica's Osmolex,
with their large cash position (includes funding from HealthCare Royalty Partners and $ 134 million secondary offering) providing us additional downside cushion.
As I recall, your comparisons concluded that the portfolio
with a larger cash position still performed fairly well with much less volatility.
Not exact matches
I began buying back
large positions with the
cash I had sitting out.
Well, she's never let me down, about 40 % of her market cap consists of
cash, I currently have a 265 % gain on my average entry price, I see 30 % upside from the current price (
with a secondary price target that offers 68 % upside), and it's my
largest portfolio
position at 7.6 %!